Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent

20013,683 citationsJournal Articlebronze Open Access

Authors

Joseph Keane · Boston University

Sharon K. Gershon

Robert P. Wise

Elizabeth Mirabile‐Levens · Pulmonary Associates

John Kasznica · Boston University

William D. Schwieterman

Jeffrey Siegel

M. Miles Braun

Abstract

Active tuberculosis may develop soon after the initiation of treatment with infliximab. Before prescribing the drug, physicians should screen patients for latent tuberculosis infection or disease.

Topics & Keywords

Tuberculosis Research and Epidemiology Infectious Diseases and Tuberculosis Mycobacterium research and diagnosis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 345, Issue 15, pp. 1098-1104

DOI: 10.1056/nejmoa011110

Field-Weighted Citation Impact: 119.21